explore -WSS

explore

author：explore 2025-09-29 22:36:39 - browse：1275

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Akili, maker of video game for ADHD, to be acquired for 34 million

entertainment

WSS

Adam's Biotech Scorecard: Do Sarepta's exon

Morgan Health, with ambitious aims, wants you to know it’s still here

3 medical device trends to watch in 2024

JPM: CVS says Medicare Advantage patients are impacting profits

Goldman Sachs launches $650M fund for life science investments

Federal weight loss drug coverage is 30 years out of date

knowledge

explore

explore

New air purifier tech could be key to improving indoor air quality

Akili, maker of video game for ADHD, to be acquired for 34 million

Drug repurposing or repositioning? The language matters

AI used to predict Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ahead of JPM, here's who's profiting most in health care

Trump demands the U.S. pay no more for drugs than other countries … again

Burning questions for the 2024 JPM Healthcare Conference

Cancer drug shortages should be causing more outrage

Dark money group runs ads on China biotech bill

hotspot

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

UCB departs biotech trade group BIO

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Startling documents reveal new facets of Sacklers' opioid empire

First Opinion Podcast: What happens when kids become caregivers?

Latest bird flu infection made farmworker sicker than earlier cases

entertainment

explore

leisure time

focus